Ataklte F, Erqou S, Laukkanen J, et al. Meta-analysis of ventricular premature complexes and their relation to cardiac mortality in gen- eral populations. Am J Cardiol. 2013;112:1263 70. S2.2.2-10. Lin CY, Chang SL, Lin YJ, et al. Long-term outcome of multiform premature ventricular complexes in structurally normal heart. Int J Cardiol. 2015;180:80 5. S2.2.2-11. Lin CY, Chang SL, Chung FP, et al. Long-term outcome of non- sustained ventricular tachycardia in structurally normal hearts. PloS One. 2016;11:e0160181. S2.2.2-12. Ruberman W, Weinblatt E, Goldberg JD, et al. Ventricular pre- mature complexes and sudden death after myocardial infarction. Circulation. 1981;64:297 305. S2.2.2-13. Ruberman W, Weinblatt E, Goldberg JD, et al. Ventricular prema- ture beats and mortality after myocardial infarction. N Engl J Med. 1977;297:750 7. S2.2.2-14. The Cardiac Arrhythmia Suppression Trial II Investigators. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. The Cardiac Arrhythmia Suppression Trial II Investigators. N Engl J Med. 1992;327:227 33. S2.2.2-15. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med. 1991;324:781 8. S2.2.2-16. Morganroth J, Goin JE. Quinidine-related mortality in the short-to- medium-term treatment of ventricular arrhythmias. A meta-analy- sis. Circulation. 1991;84:1977 83. S2.2.2-17. Waldo AL, Camm AJ, deRuyter H, et al. Effect of d-sotalol on mor- tality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol. Lancet. 1996;348:7 12. S2.2.2-18. Ling Z, Liu Z, Su L, et al. Radiofrequency ablation versus antiarrhyth- mic medication for treatment of ventricular premature beats from the right ventricular outflow tract: prospective randomized study. Circ Arrhythm Electrophysiol. 2014;7:237 43. S2.2.2-19. Jouven X, Zureik M, Desnos M, et al. Long-term outcome in asymp- tomatic men with exercise-induced premature ventricular depolar- izations. N Engl J Med. 2000;343:826 33. S2.2.2-20. Frolkis JP, Pothier CE, Blackstone EH, et al. Frequent ventricu- lar ectopy after exercise as a predictor of death. N Engl J Med. 2003;348:781 90. S2.2.2-21. Biffi A, Pelliccia A, Verdile L, et al. Long-term clinical significance of frequent and complex ventricular tachyarrhythmias in trained ath- letes. J Am Coll Cardiol. 2002;40:446 52. S2.2.2-22. Heidb chel H, Hoogsteen J, Fagard R, et al. High prevalence of right ventricular involvement in endurance athletes with ventricular arrhythmias: role of an electrophysiologic study in risk stratification. Eur Heart J. 2003;24:1473 80. S2.2.2-23. Kanei Y, Friedman M, Ogawa N, et al. Frequent premature ventricu- lar complexes originating from the right ventricular outflow tract are associated with left ventricular dysfunction. Ann Noninvasive Electrocardiol. 2008;13:81 5. S2.2.2-24. Lee GK, Klarich KW, Grogan M, et al. Premature ventricular contrac- tion-induced cardiomyopathy: a treatable condition. Circ Arrhythm Electrophysiol. 2012;5:229 36. S2.2.2-25. Viskin S, Rosso R, Rogowski O, et al. The short-coupled variant of right ventricular outflow ventricular tachycardia: a not-so-benign form of benign ventricular tachycardia? J Cardiovasc Electrophysiol. 2005;16:912 6. S2.2.2-26. Noda T, Shimizu W, Taguchi A, et al. Malignant entity of idiopathic ventricular fibrillation and polymorphic ventricular tachycardia initi- ated by premature extrasystoles originating from the right ventricu- lar outflow tract. J Am Coll Cardiol. 2005;46:1288 94. S2.2.2-27. Dumas F, Cariou A, Manzo-Silberman S, et al. Immediate percuta- neous coronary intervention is associated with better survival after out-of-hospital cardiac arrest: insights from the PROCAT (Parisian Region Out of hospital Cardiac ArresT) registry. Circ Cardiovasc Interv. 2010;3:200 7. S2.2.2-28. Gupta S, Pressman GS, Figueredo VM. Incidence of, predictors for, and mortality associated with malignant ventricular arrhythmias in non-ST elevation myocardial infarction patients. Coron Artery Dis. 2010;21:460 5. S2.2.2-29. Terkelsen CJ, Sorensen JT, Kaltoft AK, et al. Prevalence and sig- nificance of accelerated idioventricular rhythm in patients with ST-elevation myocardial infarction treated with primary percutane- ous coronary intervention. Am J Cardiol. 2009;104:1641 6. S2.2.2-30. Al-Khatib SM, Granger CB, Huang Y, et al. Sustained ventricular arrhythmias among patients with acute coronary syndromes with no ST-segment elevation: incidence, predictors, and outcomes. Circulation. 2002;106:309 12. S2.2.2-31. Jabbari R, Engstrom T, Glinge C, et al. Incidence and risk factors of ventricular fibrillation before primary angioplasty in patients with first ST-elevation myocardial infarction: a nationwide study in Denmark. J Am Heart Assoc. 2015;4:e001399. S2.2.2-32. Mehta RH, Starr AZ, Lopes RD, et al. Incidence of and outcomes associated with ventricular tachycardia or fibrillation in patients undergoing primary percutaneous coronary intervention. JAMA. 2009;301:1779 89. S2.2.2-33. Volpi A, Cavalli A, Franzosi MG, et al. One-year prognosis of primary ventricular fibrillation complicating acute myocardial infarction. The GISSI (Gruppo Italiano per lo Studio della Streptochinasi nell Infarto miocardico) investigators. Am J Cardiol. 1989;63:1174 8. S2.2.2-34. El-Sherif N, Smith RA, Evans K. Canine ventricular arrhythmias in the late myocardial infarction period. 8. Epicardial mapping of reentrant circuits. Circ Res. 1981;49:255 65. S2.2.2-35. Ackerman MJ, Priori SG, Willems S, et al. HRS/EHRA expert consen- sus statement on the state of genetic testing for the channelopathies and cardiomyopathies: this document was developed as a partner- ship between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Europace. 2011;13:1077 109. S2.2.2-36. Nannenberg EA, Sijbrands EJ, Dijksman LM, et al. Mortality of inher- ited arrhythmia syndromes: insight into their natural history. Circ Cardiovasc Genet. 2012;5:183 9. S2.2.2-37. Ha ssaguerre M, Shah DC, Jais P, et al. Role of Purkinje conduct- ing system in triggering of idiopathic ventricular fibrillation. Lancet. 2002;359:677 8. S2.2.2-38. Ha ssaguerre M, Shoda M, Jais P, et al. Mapping and ablation of idiopathic ventricular fibrillation. Circulation. 2002;106:962 7. S2.2.2-39. Goldberger JJ, Buxton AE, Cain M, et al. Risk stratification for arrhythmic sudden cardiac death: identifying the roadblocks. Circulation. 2011;123:2423 30. S2.2.2-40. Fishman GI, Chugh SS, DiMarco JP, et al. Sudden cardiac death pre- diction and prevention: report from a National Heart, Lung, and Blood Institute and Heart Rhythm Society Workshop. Circulation. 2010;122:2335 48. S2.2.2-41. Myerburg RJ. Sudden cardiac death: exploring the limits of our knowledge. J Cardiovasc Electrophysiol. 2001;12:369 81. S2.2.2-42. Kong MH, Fonarow GC, Peterson ED, et al. Systematic review of the incidence of sudden cardiac death in the United States. J Am Coll Cardiol. 2011;57:794 801. S2.2.2-43. Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics 2016 update: a report from the American Heart Association. Circulation. 2016;133:e38 360. S2.2.2-44. Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heart disease and stroke statistics 2017 update: a report from the American Heart Association. Circulation. 2017;135:e146 603. S2.2.2-45. Merchant RM, Yang L, Becker LB, et al. Incidence of treated cardiac arrest in hospitalized patients in the United States. Crit Care Med. 2011;39:2401 6. S2.2.2-46. Institute of Medicine. Committee on the Treatment of Cardiac Arrest: Current Status and Future Directions: Strategies to improve cardiac CLINICAL STATEMENTS AND GUIDELINES arrest survival: a time to act. Washington, DC: National Academic Press, 2015. S2.2.2-47. Jollis JG, Granger CB. Improving care of out-of-hospital cardiac arrest: next steps. Circulation. 2016;134:2040 2. S2.2.2-48. Daya MR, Schmicker R, May SH, et al. Current burden of cardiac arrest in the United States: report from the Resuscitation Outcomes Consortium. Paper commissioned by the Committee on the Treatment of Cardiac Arrest: Current Status and Future Directions. 2015. S2.2.2-49. Myerburg RJ, Halperin H, Egan DA, et al. Pulseless electric activity: definition, causes, mechanisms, management, and research priori- ties for the next decade: report from a National Heart, Lung, and Blood Institute workshop. Circulation. 2013;128:2532 41. S2.2.2-50. Myerburg RJ, Goldberger JJ. Sudden cardiac arrest risk assessment: population science and the individual risk mandate. JAMA Cardiol. 2017;2:689 94. S2.2.2-51. Bogle BM, Ning H, Mehrotra S, et al. Lifetime risk for sudden cardiac death in the community. J Am Heart Assoc. 2016;5:e002398. S2.2.2-52. Junttila MJ, Hookana E, Kaikkonen KS, et al. Temporal trends in the clinical and pathological characteristics of victims of sudden car- diac death in the absence of previously identified heart disease. Circ Arrhythm Electrophysiol. 2016;9:e003723. S2.2.2-53. Hookana E, Junttila MJ, Puurunen VP, et al. Causes of nonisch- emic sudden cardiac death in the current era. Heart Rhythm. 2011;8:1570 5. S2.2.2-54. Wong MK, Morrison LJ, Qiu F, et al. Trends in short- and long-term survival among out-of-hospital cardiac arrest patients alive at hospi- tal arrival. Circulation. 2014;130:1883 90. 3. MECHANISMS OF VA S3.4-1. Cherry EM, Fenton FH, Gilmour RF Jr. Mechanisms of ventricular arrhythmias: a dynamical systems-based perspective. Am J Physiol Heart Circ Physiol. 2012;302:H2451 63. S3.4-2. Pandit SV, Jalife J. Rotors and the dynamics of cardiac fibrillation. Circ Res. 2013;112:849 62. S3.4-3. Tsuji Y, Heijman J, Nattel S, et al. Electrical storm: recent pathophysi- ological insights and therapeutic consequences. Basic Res Cardiol. 2013;108:336. S3.4-4. Roden DM. Predicting drug-induced QT prolongation and torsades de pointes. J Physiol. 2016;594:2459 68. S3.4-5. Antzelevitch C, Nesterenko V, Shryock JC, et al. The role of late I Na in development of cardiac arrhythmias. Handb Exp Pharmacol. 2014;221:137 68. S3.4-6. Lerman BB. Mechanism, diagnosis, and treatment of outflow tract tachycardia. Nat Rev Cardiol. 2015;12:597 608. S3.4-7. Priori SG, Chen SR. Inherited dysfunction of sarcoplasmic reticulum Ca2+ handling and arrhythmogenesis. Circ Res. 2011;108:871 83. S3.4-8. Nogami A. Purkinje-related arrhythmias part I: monomorphic ven- tricular tachycardias. Pacing Clin Electrophysiol. 2011;34:624 50. S3.4-9. Haissaguerre M, Vigmond E, Stuyvers B, et al. Ventricular arrhyth- mias and the His-Purkinje system. Nat Rev Cardiol. 2016;13:155 66. S3.4-10. Tabereaux PB, Dosdall DJ, Ideker RE. Mechanisms of VF mainte- nance: wandering wavelets, mother rotors, or foci. Heart Rhythm. 2009;6:405 15. S3.4-11. Zhang J, Cooper DH, Desouza KA, et al. Electrophysiologic scar sub- strate in relation to VT: noninvasive high-resolution mapping and risk assessment with ECGI. Pacing Clin Electrophysiol. 2016;39:781 91. S3.4-12. Fernandez-Armenta J, Penela D, Acosta J, et al. Substrate modi- fication or ventricular tachycardia induction, mapping, and ablation as the first step? A randomized study. Heart Rhythm. 2016;13:1589 95. 4. GENERAL EVALUATION OF PATIENTS WITH DOCUMENTED OR SUSPECTED VA 4.1. History and Physical Examination S4.1-1. Middlekauff HR, Stevenson WG, Stevenson LW, et al. Syncope in advanced heart failure: high risk of sudden death regardless of ori- gin of syncope. J Am Coll Cardiol. 1993;21:110 6. S4.1-2. Myerburg RJ, Castellanos A. Cardiac arrest and sudden cardiac death - Chapter 39. Mann DL, Zipes DP, Libby P, et al, editors. Braunwald s Heart Disease: A Textbook of Cardiovascular Medicine. 10th ed. Oxford, UK: Elsevier, 2015:821 60. S4.1-3. Shen WK, Sheldon RS, Benditt DG, et al. 2017 ACC/AHA/HRS guideline for the evaluation and management of patients with syncope: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation. 2017;136:e60 122. S4.1-4. Soteriades ES, Evans JC, Larson MG, et al. Incidence and prognosis of syncope. N Engl J Med. 2002;347:878 85. S4.1-5. Noda T, Shimizu W, Taguchi A, et al. Malignant entity of idiopathic ventricular fibrillation and polymorphic ventricular tachycardia initi- ated by premature extrasystoles originating from the right ventricu- lar outflow tract. J Am Coll Cardiol. 2005;46:1288 94. S4.1-6. Viskin S, Rosso R, Rogowski O, et al. The short-coupled variant of right ventricular outflow ventricular tachycardia: a not-so-benign form of benign ventricular tachycardia? J Cardiovasc Electrophysiol. 2005;16:912 6. S4.1-7. Zimetbaum P, Josephson ME. Evaluation of patients with palpita- tions. N Engl J Med. 1998;338:1369 73. S4.1-8. Credible meds. Available at: http://www.crediblemeds.org. Accessed December 26, 2016. S4.1-9. Brugada drugs. Available at: http://www.brugadadrugs.org. Accessed October 6, 2016. S4.1-10. Konigstein M, Rosso R, Topaz G, et al. Drug-induced Brugada syndrome: clinical characteristics and risk factors. Heart Rhythm. 2016;13:1083 7. S4.1-11. Basso C, Perazzolo MM, Rizzo S, et al. Arrhythmic mitral valve pro- lapse and sudden cardiac death. Circulation. 2015;132:556 66. S4.1-12. Nordhues BD, Siontis KC, Scott CG, et al. Bileaflet mitral valve pro- lapse and risk of ventricular dysrhythmias and death. J Cardiovasc Electrophysiol. 2016;27:463 8. S4.1-13. Sriram CS, Syed FF, Ferguson ME, et al. Malignant bileaflet mitral valve prolapse syndrome in patients with otherwise idiopathic out- of-hospital cardiac arrest. J Am Coll Cardiol. 2013;62:222 30. S4.1-14. Huikuri HV, Castellanos A, Myerburg RJ. Sudden death due to car- diac arrhythmias. N Engl J Med. 2001;345:1473 82. S4.1-15. Krahn AD, Healey JS, Simpson CS, et al. Sentinel symptoms in patients with unexplained cardiac arrest: from the Cardiac Arrest Survivors with Preserved Ejection Fraction Registry (CASPER). J Cardiovasc Electrophysiol. 2012;23:60 6. S4.1-16. Ruwald MH, Hansen ML, Lamberts M, et al. The relation between age, sex, comorbidity, and pharmacotherapy and the risk of syn- cope: a Danish nationwide study. Europace. 2012;14:1506 14. 4.2. Noninvasive Evaluation 4.2.1. 12-lead ECG and Exercise Testing S4.2.1-1. Brugada P, Brugada J, Mont L, et al. A new approach to the differ- ential diagnosis of a regular tachycardia with a wide QRS complex. Circulation. 1991;83:1649 59. S4.2.1-2. Wellens HJ, Bar FW, Lie KI, The value of the electrocardiogram in the differential diagnosis of a tachycardia with a widened QRS complex. Am J Med. 1978;64:27 33. S4.2.1-3. Steinman RT, Herrera C, Schuger CD, et al. Wide QRS tachycardia in the conscious adult. Ventricular tachycardia is the most frequent cause. JAMA. 1989;261:1013 6. S4.2.1-4. Elhendy A, Chandrasekaran K, Gersh BJ, et al. Functional and prognostic significance of exercise-induced ventricular arrhythmias in patients with suspected coronary artery disease. Am J Cardiol. 2002;90:95 100. S4.2.1-5. Grady TA, Chiu AC, Snader CE, et al. Prognostic significance of exer- cise-induced left bundle-branch block. JAMA. 1998;279:153 6. S4.2.1-6. Perez-Rodon J, Martinez-Alday J, Baron-Esquivias G, et al. Prognostic value of the electrocardiogram in patients with syncope: data from the group for syncope study in the emergency room (GESINUR). Heart Rhythm. 2014;11:2035 44. S4.2.1-7. Baldasseroni S, Opasich C, Gorini M, et al. Left bundle-branch block is associated with increased 1-year sudden and total mortal- ity rate in 5517 outpatients with congestive heart failure: a report from the Italian network on congestive heart failure. Am Heart J. 2002;143:398 405. CLINICAL STATEMENTS AND GUIDELINES S4.2.1-8. Buxton AE, Sweeney MO, Wathen MS, et al. QRS duration does not predict occurrence of ventricular tachyarrhythmias in patients with implanted cardioverter-defibrillators. J Am Coll Cardiol. 2005;46:310 6. S4.2.1-9. Desai AD, Yaw TS, Yamazaki T, et al. Prognostic significance of quantitative QRS duration. Am J Med. 2006;119:600 6. S4.2.1-10. Dhar R, Alsheikh-Ali AA, Estes NA 3rd, et al. Association of pro- longed QRS duration with ventricular tachyarrhythmias and sud- den cardiac death in the Multicenter Automatic Defibrillator Implantation Trial II (MADIT-II). Heart Rhythm. 2008;5:807 13. S4.2.1-11. Freedman RA, Alderman EL, Sheffield LT, et al. Bundle branch block in patients with chronic coronary artery disease: angiographic corre- lates and prognostic significance. J Am Coll Cardiol. 1987;10:73 80. S4.2.1-12. Iuliano S, Fisher SG, Karasik PE, et al. QRS duration and mor- tality in patients with congestive heart failure. Am Heart J. 2002;143:1085 91. S4.2.1-13. Kadish A, Dyer A, Daubert JP, et al. Prophylactic defibrillator implan- tation in patients with nonischemic dilated cardiomyopathy. N Engl J Med. 2004;350:2151 8. S4.2.1-14. Zimetbaum PJ, Buxton AE, Batsford W, et al. Electrocardiographic predictors of arrhythmic death and total mortality in the multicenter unsustained tachycardia trial. Circulation. 2004;110:766 9. S4.2.1-15. Costantini O, Hohnloser SH, Kirk MM, et al. The ABCD (Alternans Before Cardioverter Defibrillator) Trial: strategies using T-wave alter- nans to improve efficiency of sudden cardiac death prevention. J Am Coll Cardiol. 2009;53:471 9. S4.2.1-16. Monasterio V, Martinez JP, Laguna P, et al. Prognostic value of average T-wave alternans and QT variability for cardiac events in MADIT-II patients. J Electrocardiol. 2013;46:480 6. S4.2.1-17. Chow T, Kereiakes DJ, Onufer J, et al. Does microvolt T-wave alter- nans testing predict ventricular tachyarrhythmias in patients with ischemic cardiomyopathy and prophylactic defibrillators? The MASTER (Microvolt T Wave Alternans Testing for Risk Stratification of Post-Myocardial Infarction Patients) trial. J Am Coll Cardiol. 2008;52:1607 15. S4.2.1-18. Gupta A, Hoang DD, Karliner L, et al. Ability of microvolt T-wave alternans to modify risk assessment of ventricular tachyarrhythmic events: a meta-analysis. Am Heart J. 2012;163:354 64. S4.2.1-19. Bloomfield DM, Steinman RC, Namerow PB, et al. Microvolt T-wave alternans distinguishes between patients likely and patients not likely to benefit from implanted cardiac defibrillator therapy: a solu- tion to the Multicenter Automatic Defibrillator Implantation Trial (MADIT) II conundrum. Circulation. 2004;110:1885 9. 4.2.2. Ambulatory Electrocardiography S4.2.2-1. Barrett PM, Komatireddy R, Haaser S, et al. Comparison of 24-hour Holter monitoring with 14-day novel adhesive patch electrocardio- graphic monitoring. Am J Med. 2014;127:95 7. S4.2.2-2. de Asmundis C, Conte G, Sieira J, et al. Comparison of the patient- activated event recording system vs. traditional 24 h Holter elec- trocardiography in individuals with paroxysmal palpitations or dizziness. Europace. 2014;16:1231 5. S4.2.2-3. Linzer M, Pritchett EL, Pontinen M, et al. Incremental diagnostic yield of loop electrocardiographic recorders in unexplained syncope. Am J Cardiol. 1990;66:214 9. S4.2.2-4. Turakhia MP, Hoang DD, Zimetbaum P, et al. Diagnostic utility of a novel leadless arrhythmia monitoring device. Am J Cardiol. 2013;112:520 4. 4.2.3. Implanted Cardiac Monitors S4.2.3-1. Bloch Thomsen PE, Jons C, Raatikainen MJ, et al. Long-term recording of cardiac arrhythmias with an implantable cardiac monitor in patients with reduced ejection fraction after acute myo- cardial infarction: the Cardiac Arrhythmias and Risk Stratification After Acute Myocardial Infarction (CARISMA) study. Circulation. 2010;122:1258 64. S4.2.3-2. Krahn AD, Klein GJ, Yee R, et al. Use of an extended monitoring strategy in patients with problematic syncope. Reveal Investigators. Circulation. 1999;99:406 10. S4.2.3-3. Solbiati M, Costantino G, Casazza G, et al. Implantable loop recorder versus conventional diagnostic workup for unexplained recurrent syncope. Cochrane Database Syst. Rev. 2016;4:CD011637. S4.2.3-4. Volosin K, Stadler RW, Wyszynski R, et al. Tachycardia detection performance of implantable loop recorders: results from a large real-life patient cohort and patients with induced ventricular arrhythmias. Europace. 2013;15:1215 22. S4.2.3-5. Linzer M, Pritchett EL, Pontinen M, et al. Incremental diagnostic yield of loop electrocardiographic recorders in unexplained syncope. Am J Cardiol. 1990;66:214 9. S4.2.3-6. Turakhia MP, Hoang DD, Zimetbaum P, et al. Diagnostic utility of a novel leadless arrhythmia monitoring device. Am J Cardiol. 2013;112:520 4. 4.2.4. Noninvasive Cardiac Imaging S4.2.4-1. Solomon SD, Zelenkofske S, McMurray JJ, et al. Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med. 2005;352:2581 8. S4.2.4-2. Gula LJ, Klein GJ, Hellkamp AS, et al. Ejection fraction assessment and survival: an analysis of the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Am Heart J. 2008;156:1196 200. S4.2.4-3. Rauch B, Schiele R, Schneider S, et al. OMEGA, a randomized, pla- cebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myo- cardial infarction. Circulation. 2010;122:2152 9. S4.2.4-4. Shen WK, Sheldon RS, Benditt DG, et al. 2017 ACC/AHA/HRS guideline for the evaluation and management of patients with syncope: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation. 2017;136:e60 122. S4.2.4-5. Coleman GC, Shaw PW, Balfour PC Jr, et al. Prognostic value of myocardial scarring on CMR in patients with cardiac sarcoidosis: a systematic review and meta-analysis. JACC Cardiovasc Imaging. 2016;10:411 20. S4.2.4-6. Di Marco A, Anguera I, Schmitt M, et al. Late gadolinium enhance- ment and the risk for ventricular arrhythmias or sudden death in dilated cardiomyopathy: systematic review and meta-analysis. JACC Heart Fail. 2017;5:28 38. S4.2.4-7. Greulich S, Deluigi CC, Gloekler S, et al. CMR imaging predicts death and other adverse events in suspected cardiac sarcoidosis. JACC Cardiovasc Imaging. 2013;6:501 11. S4.2.4-8. Piers SR, Tao Q, van Huls van Taxis CF, et al. Contrast-enhanced MRI-derived scar patterns and associated ventricular tachycardias in nonischemic cardiomyopathy: implications for the ablation strategy. Circ Arrhythm Electrophysiol. 2013;6:875 83. S4.2.4-9. White JA, Fine NM, Gula L, et al. Utility of cardiovascular magnetic resonance in identifying substrate for malignant ventricular arrhyth- mias. Circ Cardiovasc imaging. 2012;5:12 20. S4.2.5-1. Ahmad T, Fiuzat M, Neely B, et al. Biomarkers of myocardial stress and fibrosis as predictors of mode of death in patients with chronic heart failure. JACC Heart Fail. 2014;2:260 8. S4.2.5-2. Scott PA, Barry J, Roberts PR, et al. Brain natriuretic peptide for the prediction of sudden cardiac death and ventricular arrhythmias: a meta-analysis. Eur J Heart Fail. 2009;11:958 66. S4.2.5-3. Levine YC, Rosenberg MA, Mittleman M, et al. B-type natriuretic peptide is a major predictor of ventricular tachyarrhythmias. Heart Rhythm. 2014;11:1109 16. S4.2.5-4. Berger R, Huelsman M, Strecker K, et al. B-type natriuretic pep- tide predicts sudden death in patients with chronic heart failure. Circulation. 2002;105:2392 7. S4.2.5-5. Korngold EC, Januzzi JL Jr, Gantzer ML, et al. Amino-terminal pro- B-type natriuretic peptide and high-sensitivity C-reactive protein as predictors of sudden cardiac death among women. Circulation. 2009;119:2868 76. S4.2.5-6. Patton KK, Sotoodehnia N, DeFilippi C, et al. N-terminal pro-B-type natriuretic peptide is associated with sudden cardiac death risk: the Cardiovascular Health Study. Heart Rhythm. 2011;8:228 33. S4.2.5-7. Hussein AA, Gottdiener JS, Bartz TM, et al. Cardiomyocyte injury assessed by a highly sensitive troponin assay and sudden cardiac death in the community: the Cardiovascular Health Study. J Am Coll Cardiol. 2013;62:2112 20. 4.2.6. Genetic Considerations in Arrhythmia Syndromes S4.2.6-1. Andreasen C, Refsgaard L, Nielsen JB, et al. Mutations in genes encoding cardiac ion channels previously associated with sudden CLINICAL STATEMENTS AND GUIDELINES infant death syndrome (SIDS) are present with high frequency in new exome data. Can J Cardiol. 2013;29:1104 9. S4.2.6-2. Jabbari J, Jabbari R, Nielsen MW, et al. New exome data question the pathogenicity of genetic variants previously associated with cat- echolaminergic polymorphic ventricular tachycardia. Circ Cardiovas Genetics. 2013 481 9. S4.2.6-3. Paludan-Muller C, Ahlberg G, Ghouse J, et al. Integration of 60000 exomes and ACMG guidelines question the role of catecholamin- ergic polymorphic ventricular tachycardia-associated variants. Clin Genet. 2017;91:63 72. S4.2.6-4. Refsgaard L, Holst AG, Sadjadieh G, et al. High prevalence of genetic variants previously associated with LQT syndrome in new exome data. Eur J Hum Genet. 2012;20:905 8. S4.2.6-5. Risgaard B, Jabbari R, Refsgaard L, et al. High prevalence of genetic variants previously associated with Brugada syndrome in new exome data. Clin Genet. 2013;84:489 95. S4.2.6-6. Costa J, Lopes CM. Barsheshet A, et al. Combined assessment of sex- and mutation-specific information for risk stratification in type 1 long QT syndrome. Heart Rhythm. 2012;9:892 8. S4.2.6-7. Hershberger RE, Lindenfeld J, Mestroni L, et al. Genetic evalua- tion of cardiomyopathy a Heart Failure Society of America practice guideline. J Cardiac Fail. 2009;15:83 97. S4.2.6-8. Kim JA, Lopes CM, Moss AJ, et al. Trigger-specific risk factors and response to therapy in long QT syndrome type 2. Heart Rhythm. 2010;7:1797 805. S4.2.6-9. Migdalovich D, Moss AJ, Lopes CM, et al. Mutation and gender- specific risk in type 2 long QT syndrome: implications for risk strati- fication for life-threatening cardiac events in patients with long QT syndrome. Heart Rhythm. 2011;8:1537 43. S4.2.6-10. Crotti L, Marcou CA, Tester DJ, et al. Spectrum and prevalence of muta- tions involving BrS1- through BrS12-susceptibility genes in a cohort of unrelated patients referred for Brugada syndrome genetic testing: implications for genetic testing. J Am Coll Cardiol. 2012;60:1410 8. S4.2.6-11. Probst V, Wilde AA, Barc J, et al. SCN5A mutations and the role of genetic background in the pathophysiology of Brugada syndrome. Circ Cardiovas Genetics. 2009;2:552 7. S4.2.6-12. Dintzis RZ. Genetic variation and the meiotic process. Res Publ Assoc Res Nerv Ment Dis. 1991;69:39 46. S4.2.6-13. Groeneweg JA, Bhonsale A, James CA, et al. Clinical presentation, long-term follow-up, and outcomes of 1001 arrhythmogenic right ventricular dysplasia/cardiomyopathy patients and family members. Circ Cardiovasc Genet. 2015;8:437 46. S4.2.6-14. Marcus FI, Edson S, Towbin JA. Genetics of arrhythmogenic right ventricular cardiomyopathy: a practical guide for physicians. J Am Coll Cardiol. 2013;61:1945 8. S4.2.6-15. Quarta G, Muir A, Pantazis A, et al. Familial evaluation in arrhyth- mogenic right ventricular cardiomyopathy: impact of genetics and revised task force criteria. Circulation. 2011;123:2701 9. S4.2.6-16. Rigato I, Bauce B, Rampazzo A, et al. Compound and digenic heterozygosity predicts lifetime arrhythmic outcome and sudden cardiac death in desmosomal gene-related arrhythmogenic right ventricular cardiomyopathy. Circ Cardiovasc Genet. 2013;6:533 42. S4.2.6-17. Ackerman MJ, Priori SG, Willems S, et al. HRS/EHRA expert consen- sus statement on the state of genetic testing for the channelopathies and cardiomyopathies: this document was developed as a partner- ship between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Europace. 2011;13:1077 109. S4.2.6-18. Gollob MH, Blier L, Brugada R, et al. Recommendations for the use of genetic testing in the clinical evaluation of inherited car- diac arrhythmias associated with sudden cardiac death: Canadian Cardiovascular Society/Canadian Heart Rhythm Society joint posi- tion paper. Can J Cardiol. 2011;27:232 45. S4.2.6-19. Kumar S, Peters S, Thompson T, et al. Familial cardiological and tar- geted genetic evaluation: low yield in sudden unexplained death and high yield in unexplained cardiac arrest syndromes. Heart Rhythm. 2013;10:1653 60. S4.2.6-20. Priori SG, Wilde AA, Horie M, et al. HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes. Heart Rhythm. 2013;10:1932 63. S4.2.6-21. Tester DJ, Medeiros-Domingo A, Will ML, et al. Unexplained drown- ings and the cardiac channelopathies: a molecular autopsy series. Mayo Clin Proc. 2011;86:941 7. S4.2.6-22. Tzimas I, Zingraf JC, Bajanowski T, et al. The role of known variants deaths. Int J Legal Med. 2016;130:1575 9. S4.2.6-23. Wang D, Shah KR, Um SY, et al. Cardiac channelopathy testing in 274 ethnically diverse sudden unexplained deaths. Forensic Sci Int. 2014;237:90 9. S4.2.6-24. Laedtke AL, O Neill SM, Rubinstein WS, et al. Family physicians awareness and knowledge of the Genetic Information Non- Discrimination Act (GINA). J Genet Couns. 2012;21:345 52. S4.2.6-25. Vavolizza RD, Kalia I, Erskine AK, et al. Disclosing genetic informa- tion to family members about inherited cardiac arrhythmias: an obli- gation or a choice? J Genet Couns. 2015;24:608 15. S4.2.6-26. Christiaans I, van Langen IM, Birnie E, et al. Genetic counseling and cardiac care in predictively tested hypertrophic cardiomyopathy mutation carriers: the patients perspective. Am J Med Genet. Part A. 2009;149a: 1444 51. S4.2.6-27. Hamang A, Eide GE, Rokne B, et al. Predictors of heart-focused anxiety in patients undergoing genetic investigation and counseling of long QT syndrome or hypertrophic cardiomyopathy: a one year follow-up. J Genet Counsel. 2012;21:72 84. 4.3. Invasive Testing 4.3.1. Invasive Cardiac Imaging: Cardiac Catheterization or CT Angiography S4.3.1-1. Dumas F, Bougouin W, Geri G, et al. Emergency PCI in post-cardiac arrest patients without ST-segment elevation pattern: insights from the PROCAT II registry. JACC Cardiovasc Interv. 2016;9:1011 8. S4.3.1-2. Cronier P, Vignon P, Bouferrache K, et al. Impact of routine percuta- neous coronary intervention after out-of-hospital cardiac arrest due to ventricular fibrillation. Crit Care. 2011;15:R122. S4.3.1-3. Spaulding CM, Joly LM, Rosenberg A, et al. Immediate coronary angiography in survivors of out-of-hospital cardiac arrest. N Engl J Med. 1997;336:1629 33. S4.3.1-4. Zanuttini D, Armellini I, Nucifora G, et al. Impact of emergency coro- nary angiography on in-hospital outcome of unconscious survivors after out-of-hospital cardiac arrest. Am J Cardiol. 2012;110:1723 8. S4.3.1-5. O Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guide- line for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;127:e362 425. 4.3.2. Electrophysiological Study for VA S4.3.2-1. Buxton AE, Lee KL, DiCarlo L, et al. Electrophysiologic testing to identify patients with coronary artery disease who are at risk for sud- den death. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med. 2000;342:1937 45. S4.3.2-2. Buxton AE, Lee KL, Hafley GE, et al. Relation of ejection fraction and inducible ventricular tachycardia to mode of death in patients with coronary artery disease: an analysis of patients enrolled in the multi- center unsustained tachycardia trial. Circulation. 2002;106:2466 72. S4.3.2-3. Costantini O, Hohnloser SH, Kirk MM, et al. The ABCD (Alternans Before Cardioverter Defibrillator) Trial: strategies using T-wave alter- nans to improve efficiency of sudden cardiac death prevention. J Am Coll Cardiol. 2009;53:471 9. S4.3.2-4. Bourke JP, Richards DA, Ross DL, et al. Routine programmed electri- cal stimulation in survivors of acute myocardial infarction for predic- tion of spontaneous ventricular tachyarrhythmias during follow-up: results, optimal stimulation protocol and cost-effective screening. J Am Coll Cardiol. 1991;18:780 8. S4.3.2-5. Bailey JJ, Berson AS, Handelsman H, et al. Utility of current risk stratification tests for predicting major arrhythmic events after myo- cardial infarction. J Am Coll Cardiol. 2001;38:1902 11. S4.3.2-6. Schmitt C, Barthel P, Ndrepepa G, et al. Value of programmed ven- tricular stimulation for prophylactic internal cardioverter-defibrillator implantation in postinfarction patients preselected by noninvasive risk stratifiers. J Am Coll Cardiol. 2001;37:1901 7. S4.3.2-7. Hilfiker G, Schoenenberger AW, Erne P, et al. Utility of electro- physiological studies to predict arrhythmic events. World J Cardiol. 2015;7:344 50. S4.3.2-8. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225 37. S4.3.2-9. Buxton AE, Lee KL, Fisher JD, et al. A randomized study of the pre- vention of sudden death in patients with coronary artery disease. CLINICAL STATEMENTS AND GUIDELINES Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med. 1999;341:1882 90. S4.3.2-10. Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med. 1996;335:1933 40. S4.3.2-11. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejec- tion fraction. N Engl J Med. 2002;346:877 83. S4.3.2-12. Bhandari AK, Shapiro WA, Morady F, et al. Electrophysiologic testing in patients with the long QT syndrome. Circulation. 1985;71:63 71. S4.3.2-13. Giustetto C, Di MF, Wolpert C, et al. Short QT syndrome: clini- cal findings and diagnostic-therapeutic implications. Eur Heart J. 2006;27:2440 7. S4.3.2-14. Giustetto C, Schimpf R, Mazzanti A, et al. Long-term follow- up of patients with short QT syndrome. J Am Coll Cardiol. 2011;58:587 95. S4.3.2-15. Mahida S, Derval N, Sacher F, et al. Role of electrophysiological stud- ies in predicting risk of ventricular arrhythmia in early repolarization syndrome. J Am Coll Cardiol. 2015;65:151 9. S4.3.2-16. Priori SG, Napolitano C, Memmi M, et al. Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia. Circulation. 2002;106:69 74. S4.3.2-17. Gatzoulis KA, Vouliotis AI, Tsiachris D, et al. Primary prevention of sudden cardiac death in a nonischemic dilated cardiomyopathy population: reappraisal of the role of programmed ventricular stim- ulation. Circ Arrhythm Electrophysiol. 2013;6:504 12. S4.3.2-18. Brembilla-Perrot B, Suty-Selton C, Beurrier D, et al. Differences in mechanisms and outcomes of syncope in patients with coronary disease or idiopathic left ventricular dysfunction as assessed by elec- trophysiologic testing. J Am Coll Cardiol. 2004;44:594 601. S4.3.2-19. Garson A Jr, Dick M, Fournier A, et al. The long QT syndrome in children. An international study of 287 patients. Circulation. 1993;87:1866 72. S4.3.2-20. Hobbs JB, Peterson DR, Moss AJ, et al. Risk of aborted cardiac arrest or sudden cardiac death during adolescence in the long-QT syn- drome. JAMA. 2006;296:1249 54. S4.3.2-21. Iribarren C, Round AD, Peng JA, et al. Short QT in a cohort of 1.7 million persons: prevalence, correlates, and prognosis. Ann Noninvasive Electrocardiol. 2014;19:490 500. S4.3.2-22. Kaufman ES, McNitt S, Moss AJ, et al. Risk of death in the long QT syndrome when a sibling has died. Heart Rhythm. 2008;5:831 6. S4.3.2-23. Kimbrough J, Moss AJ, Zareba W, et al. Clinical implications for affected parents and siblings of probands with long-QT syndrome. Circulation. 2001;104:557 62. S4.3.2-24. Mazzanti A, Kanthan A, Monteforte N, et al. Novel insight into the natural history of short QT syndrome. J Am Coll Cardiol. 2014;63:1300 8. S4.3.2-25. Wong JA, Gula LJ, Klein GJ, et al. Utility of treadmill testing in identification and genotype prediction in long-QT syndrome. Circ Arrhythm Electrophysiol. 2010;3:120 5. S4.3.2-26. Walker BD, Krahn AD, Klein GJ, et al. Burst bicycle exercise facilitates diagnosis of latent long QT syndrome. Am Heart J. 2005;150:1059 63. S4.3.2-27. Waks JW, Sitlani CM, Soliman EZ, et al. Global electric hetero- geneity risk score for prediction of sudden cardiac death in the general population: the Atherosclerosis Risk in Communities (ARIC) and Cardiovascular Health (CHS) Studies. Circulation. 2016;133:2222 34. S4.3.2-28. Priori SG, Napolitano C, Schwartz PJ, et al. Association of long QT syndrome loci and cardiac events among patients treated with beta- blockers. JAMA. 2004;292:1341 4. S4.3.2-29. Priori SG, Schwartz PJ, Napolitano C, et al. Risk stratification in the long-QT syndrome. N Engl J Med. 2003;348:1866 74. S4.3.2-30. Wedekind H, Burde D, Zumhagen S, et al. QT interval prolongation and risk for cardiac events in genotyped LQTS-index children. Eur J Pediatr. 2009;168:1107 15. S4.3.2-31. Goldenberg I, Horr S, Moss AJ, et al. Risk for life-threatening cardiac events in patients with genotype-confirmed long-QT syn- drome and normal-range corrected QT intervals. J Am Coll Cardiol. 2011;57:51 9. S4.3.2-32. Nannenberg EA, Sijbrands EJ, Dijksman LM, et al. Mortality of inher- ited arrhythmia syndromes: insight into their natural history. Circ Cardiovasc Genet. 2012;5:183 9. 5. THERAPIES FOR TREATMENT OR PREVENTION OF VA 5.1. Medication Therapy S5.1.5.2-1. Vaughan Williams EM. A classification of antiarrhythmic actions reassessed after a decade of new drugs. J Clin Pharmacol. 1984;24:129 47. S5.1.5.2-2. Schleifer JW, Sorajja D, Shen WK. Advances in the pharmacologic treatment of ventricular arrhythmias. Expert Opin Pharmacother. 2015;16:2637 51. S5.1.5.2-3. Kudenchuk PJ, Brown SP, Daya M, et al. Amiodarone, lidocaine, or placebo in out-of-hospital cardiac arrest. N Engl J Med. 2016; 1711 22. S5.1.5.2-4. Mazzanti A, Maragna R, Faragli A, et al. Gene-specific therapy with mexiletine reduces arrhythmic events in patients with long QT syndrome type 3. J Am Coll Cardiol. 2016;67:1053 8. S5.1.5.2-5. Watanabe H, Chopra N, Laver D, et al. Flecainide prevents cat- echolaminergic polymorphic ventricular tachycardia in mice and humans. Nat Med. 2009;15:380 3. S5.1.5.2-6. Gupta T, Khera S, Kolte D, et al. Antiarrhythmic properties of ranolazine: a review of the current evidence. Int J Cardiol. 2015;187:66 74. S5.1.5.2-7. Bunch TJ, Mahapatra S, Murdock D, et al. Ranolazine reduces ventricular tachycardia burden and ICD shocks in patients with drug-refractory ICD shocks. Pacing Clin Electrophysiol. 2011;34:1600 6. S5.1.5.2-8. Scirica BM, Braunwald E, Belardinelli L, et al. Relationship between nonsustained ventricular tachycardia after non-ST-elevation acute coronary syndrome and sudden cardiac death: observations from the metabolic efficiency with ranolazine for less ischemia in non- ST-elevation acute coronary syndrome-thrombolysis in myocar- dial infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation. 2010;122:455 62. S5.1.5.2-9. Zareba W, Daubert JP, Beck CA, et al. Ranolazine in High-Risk ICD Patients (RAID) Trial. Presented at: Heart Rhythm Society Annual Scientific Sessions. 2017; LBCT02 01. S5.1.5.2-10. Reiter MJ, Reiffel JA, Importance of beta blockade in the therapy of serious ventricular arrhythmias. Am J Cardiol. 1998;82:9I 19I. S5.1.5.2-11. Ellison KE, Hafley GE, Hickey K, et al. Effect of beta-blocking ther- apy on outcome in the Multicenter UnSustained Tachycardia Trial (MUSTT). Circulation. 2002;106:2694 9. S5.1.5.2-12. Reiken S, Wehrens XH, Vest JA, et al. Beta-blockers restore cal- cium release channel function and improve cardiac muscle perfor- mance in human heart failure. Circulation. 2003;107:2459 66. S5.1.5.2-13. MERIT-HF Group Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353:2001 7. S5.1.5.2-14. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart fail- ure. US Carvedilol Heart Failure Study Group. N Engl J Med. 1996;334:1349 55. S5.1.5.2-15. Committees of the Cardiac insufficiency Bisoprolol Study II. The cardiac insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353:9 13. S5.1.5.2-16. A randomized trial of propranolol in patients with acute myocar- dial infarction. Mortality results. JAMA. 1982;247:1707 14. S5.1.5.2-17. Kontos MC, Diercks DB, Ho PM, et al. Treatment and outcomes in patients with myocardial infarction treated with acute beta- blocker therapy: results from the American College of Cardiology s NCDR(R). Am Heart J. 2011;161:864 70. S5.1.5.2-18. Nademanee K, Taylor R, Bailey WE, et al. Treating electrical storm: sympathetic blockade versus advanced cardiac life support- guided therapy. Circulation. 2000;102:742 7. S5.1.5.2-19. Krittayaphong R, Bhuripanyo K, Punlee K, et al. Effect of atenolol on symptomatic ventricular arrhythmia without structural heart disease: a randomized placebo-controlled study. Am Heart J. 2002;144:e10. S5.1.5.2-20. Hirsowitz G, Podrid PJ, Lampert S, et al. The role of beta block- ing agents as adjunct therapy to membrane stabilizing drugs in malignant ventricular arrhythmia. Am Heart J. 1986;111: 852 60. S5.1.5.2-21. Connolly SJ. Meta-analysis of antiarrhythmic drug trials. Am J Cardiol. 1999;84:90R 3R. CLINICAL STATEMENTS AND GUIDELINES S5.1.5.2-22. Steinberg JS, Martins J, Sadanandan S, et al. Antiarrhythmic drug use in the implantable defibrillator arm of the Antiarrhythmics Versus Implantable Defibrillators (AVID) Study. Am Heart J. 2001;142:520 9. S5.1.5.2-23. Farre J, Romero J, Rubio JM, et al. Amiodarone and primary prevention of sudden death: critical review of a decade of clinical trials. Am J Cardiol. 1999;83:55D 63D. S5.1.5.2-24. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implant- able cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225 37. S5.1.5.2-25. Thomas KL, Al-Khatib SM, Lokhnygina Y, et al. Amiodarone use after acute myocardial infarction complicated by heart failure and/ or left ventricular dysfunction may be associated with excess mor- tality. Am Heart J. 2008;155:87 93. S5.1.5.2-26. Claro JC, Candia R, Rada G, et al. Amiodarone versus other phar- macological interventions for prevention of sudden cardiac death. Cochrane Database Syst. Rev. 2015;12:CD008093. S5.1.5.2-27. Kudenchuk PJ, Cobb LA, Copass MK, et al. Amiodarone for resuscitation after out-of-hospital cardiac arrest due to ventricular fibrillation. N Engl J Med. 1999;341:871 8. S5.1.5.2-28. Dorian P, Cass D, Schwartz B, et al. Amiodarone as compared with lidocaine for shock-resistant ventricular fibrillation. N Engl J Med. 2002;346:884 90. S5.1.5.2-29. Levine JH, Massumi A, Scheinman MM, et al. Intravenous amioda- rone for recurrent sustained hypotensive ventricular tachyarrhyth- mias. Intravenous Amiodarone Multicenter Trial Group. J Am Coll Cardiol. 1996;27:67 75. S5.1.5.2-30. Epstein AE, Olshansky B, Naccarelli GV, et al. Practical manage- ment guide for clinicians who treat patients with amiodarone. Am J Med. 2016;129:468 75. S5.1.5.2-31. Kuhlkamp V, Mewis C, Mermi J, et al. Suppression of sustained ventricular tachyarrhythmias: a comparison of d,l-sotalol with no antiarrhythmic drug treatment. J Am Coll Cardiol. 1999;33:46 52. S5.1.5.2-32. Waldo AL, Camm AJ, deRuyter H, et al. Survival with oral d-sotalol in patients with left ventricular dysfunction after myocardial infarction: rationale, design, and methods (the SWORD trial). Am J Cardiol. 1995;75:1023 7. S5.1.5.2-33. Page RL. Effects of antiarrhythmic medication on implantable car- dioverter-defibrillator function. Am J Cardiol. 2000;85:1481 5. S5.1.5.2-34. Buxton AE, Marchlinski FE, Doherty JU, et al. Hazards of intra- venous verapamil for sustained ventricular tachycardia. Am J Cardiol. 1987;59:1107 10. S5.1.5.2-35. Belhassen BHorowitz LN. Use of intravenous verapamil for ven- tricular tachycardia. Am J Cardiol. 1984;54:1131 3. S5.1.5.2-36. Griffith MJ, Garratt CJ, Rowland E, et al. Effects of intravenous adenosine on verapamil-sensitive idiopathic ventricular tachy- cardia. Am J Cardiol. 1994;73:759 64. S5.1.5.2-37. Gill JS, Blaszyk K, Ward DE, et al. Verapamil for the suppression of idiopathic ventricular tachycardia of left bundle branch block-like morphology. Am Heart J. 1993;126:1126 33. S5.1.5.2-38. Badhwar N, Scheinman MM. Idiopathic ventricular tachycardia: diagnosis and management. Curr Probl Cardiol. 2007;32:7 43. S5.1.5.2-39. Gill JS, Ward DE, Camm AJ. Comparison of verapamil and dil- tiazem in the suppression of idiopathic ventricular tachycardia. Pacing Clin Electrophysiol. 1992;15:2122 6. S5.1.5.2-40. Investigators in the Magnesium in Coronaries (MAGIC) Trial. Early administration of intravenous magnesium to high-risk patients with acute myocardial infarction in the Magnesium in Coronaries (MAGIC) Trial: a randomised controlled trial. Lancet. 2002;360:1189 96. S5.1.5.2-41. Cooper HA, Dries DL, Davis CE, et al. Diuretics and risk of arrhyth- mic death in patients with left ventricular dysfunction. Circulation. 1999;100:1311 5. S5.1.5.2-42. Kafka H, Langevin L, Armstrong PW. Serum magnesium and potassium in acute myocardial infarction. Influence on ventricular arrhythmias. Arch Intern Med. 1987;147:465 9. S5.1.5.2-43. Yan GX, Antzelevitch C. Cellular basis for the normal T wave and the electrocardiographic manifestations of the long-QT syn- drome. Circulation. 1998;98:1928 36. S5.1.5.2-44. Tzivoni D, Banai S, Schuger C, et al. Treatment of torsade de pointes with magnesium sulfate. Circulation. 1988;77:392 7. S5.1.5.2-45. Leier CV, Dei CL, Metra M. Clinical relevance and management of the major electrolyte abnormalities in congestive heart failure: hyponatremia, hypokalemia, and hypomagnesemia. Am Heart J. 1994;128:564 74. S5.1.5.2-46. Cohn JN, Kowey PR, Whelton PK, et al. New guidelines for potas- sium replacement in clinical practice: a contemporary review by the National Council on Potassium in Clinical Practice. Arch Intern Med. 2000;160:2429 36. S5.1.5.2-47. Macdonald JE, Struthers AD. What is the optimal serum potas- sium level in cardiovascular patients? J Am Coll Cardiol. 2004;43:155 61. S5.1.5.2-48. Goyal A, Spertus JA, Gosch K, et al. Serum potassium levels and mortality in acute myocardial infarction. JAMA. 2012;307:157 64. S5.1.5.2-49. Leaf A, Kang JX, Xiao YF, et al. Clinical prevention of sudden cardiac death by n-3 polyunsaturated fatty acids and mecha- nism of prevention of arrhythmias by n-3 fish oils. Circulation. 2003;107:2646 52. S5.1.5.2-50. Mozaffarian D, Rimm EB. Fish intake, contaminants, and human health: evaluating the risks and the benefits. JAMA. 2006;296:1885 99. S5.1.5.2-51. Marchioli R, Barzi F, Bomba E, et al. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocar- dial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell Infarto Miocardico (GISSI)-Prevenzione. Circulation. 2002;105:1897 903. S5.1.5.2-52. Kromhout D, Giltay EJ, Geleijnse JM. n-3 fatty acids and car- diovascular events after myocardial infarction. N Engl J Med. 2010;363:2015 26. S5.1.5.2-53. Rauch B, Schiele R, Schneider S, et al. OMEGA, a randomized, pla- cebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction. Circulation. 2010;122:2152 9. S5.1.5.2-54. Burr ML, Ashfield-Watt PA, Dunstan FD, et al. Lack of benefit of dietary advice to men with angina: results of a controlled trial. Eur J Clin Nutr. 2003;57:193 200. S5.1.5.2-55. Galan P, Kesse-Guyot E, Czernichow S, et al. Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial. BMJ. 2010;341:c6273. S5.1.5.2-56. Bosch J, Gerstein HC, Dagenais GR, et al. n-3 fatty acids and car- diovascular outcomes in patients with dysglycemia. N Engl J Med. 2012;367:309 18. S5.1.5.2-57. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA. 1999;282:2340 6. S5.1.5.2-58. Buber J, Goldenberg I, Moss AJ, et al. Reduction in life-threatening ventricular tachyarrhythmias in statin-treated patients with non- ischemic cardiomyopathy enrolled in the MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy). J Am Coll Cardiol. 2012;60:749 55. S5.1.5.2-. 59 Investigators in TAvIDAA comparison of antiarrhythmic- drug therapy with implantable defibrillators in patients resus- citated from near-fatal ventricular arrhythmias. N Engl J Med. 1997;337:1576 83. S5.1.5.2-60. Mitchell LB, Powell JL, Gillis AM, et al. Are lipid-lowering drugs also antiarrhythmic drugs? An analysis of the Antiarrhythmics versus Implantable Defibrillators (AVID) trial. J Am Coll Cardiol. 2003;42:81 7. S5.1.5.2-61. Dickinson MG, Ip JH, Olshansky B, et al. Statin use was associated with reduced mortality in both ischemic and nonischemic cardio- myopathy and in patients with implantable defibrillators: mortal- ity data and mechanistic insights from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Am Heart J. 2007;153:573 8. S5.1.5.2-62. Goldberger JJ, Subacius H, Schaechter A, et al. Effects of statin therapy on arrhythmic events and survival in patients with nonischemic dilated cardiomyopathy. J Am Coll Cardiol. 2006;48:1228 33. S5.1.5.2-63. Kjekshus J, Apetrei E, Barrios V, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2007;357:2248 61. S5.1.5.2-64. Tavazzi L, Maggioni AP, Marchioli R, et al. Effect of rosuvas- tatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372:1231 9. 5.2. Preventing SCD With HF Medications S5.2-1. Yancy CW, Jessup M, Bozkurt B, et al. 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA guideline for the management CLINICAL STATEMENTS AND GUIDELINES of heart failure: a report of the American College of Cardiology/ American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2016;134:e282 93. S5.2-2. Committees for Cardiac insufficiency Bisoprolol Study II. The car- diac insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353:9 13. S5.2-3. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991;325:303 10. S5.2-4. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart fail- ure. US Carvedilol Heart Failure Study Group. N Engl J Med. 1996;334:1349 55. S5.2-5. Dargie HJ. Effect of carvedilol on outcome after myocardial infarc- tion in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001;357:1385 90. S5.2-6. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldo- sterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309 21. S5.2-7. Al Chekakie MO. Traditional heart failure medications and sudden cardiac death prevention: a review. J Cardiovasc Pharmacol Ther. 2013;18:412 26. S5.2-8. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, cap- topril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349:1893 906. S5.2-9. Hjalmarson A, Goldstein S, Fagerberg B, et al. Effects of controlled-release metoprolol on total mortality, hospital- izations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in conges- tive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA. 2000;283:1295 302. S5.2-10. McMurray J.J.V, stergren J, Swedberg K, et al. Effects of cande- sartan in patients with chronic heart failure and reduced left-ven- tricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet. 2003;362:767 71. S5.2-11. Cohn JN, Tognoni G. A randomized trial of the angiotensin- receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667 75. S5.2-12. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709 17. S5.2-13. Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:11 21. S5.2-14. Desai AS, McMurray JJ, Packer M, et al. Effect of the angioten- sin-receptor-neprilysin inhibitor LCZ696 compared with enala- pril on mode of death in heart failure patients. Eur Heart J. 2015;36:1990 7. 5.4. Catheter Ablation S5.4.3-1. Zeppenfeld K, Schalij MJ, Bartelings MM, et al. Catheter ablation of ventricular tachycardia after repair of congenital heart disease: electroanatomic identification of the critical right ventricular isth- mus. Circulation. 2007;116:2241 52. S5.4.3-2. Priori SG, Blomstrom-Lundqvist C, Mazzanti A, et al. 2015 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: the Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Eur Heart J. 2015;36:2793 867. S5.4.3-3. Aliot EM, Stevenson WG, Almendral-Garrote JM, et al. EHRA/HRS expert consensus on catheter ablation of ventricular arrhythmias: developed in a partnership with the European Heart Rhythm Association (EHRA), a Registered Branch of the European Society of Cardiology (ESC), and the Heart Rhythm Society (HRS); in collaboration with the American College of Cardiology (ACC) and the American Heart Association (AHA). Heart Rhythm. 2009;6:886 933. 5.5. Surgery and Revascularization Procedures in Patients With Ischemic Heart Disease S5.5-1. Cook JR, Rizo-Patron C, Curtis AB, et al. Effect of surgical revascu- larization in patients with coronary artery disease and ventricular tachycardia or fibrillation in the Antiarrhythmics Versus Implantable Defibrillators (AVID) Registry. Am Heart J. 2002;143:821 6. S5.5-2. Velazquez EJ, Lee KL, Jones RH, et al. Coronary-artery bypass surgery in patients with ischemic cardiomyopathy. N Engl J Med. 2016;374:1511 20. S5.5-3. Every NR, Fahrenbruch CE, Hallstrom AP, et al. Influence of coro- nary bypass surgery on subsequent outcome of patients resus- citated from out of hospital cardiac arrest. J Am Coll Cardiol. 1992;19:1435 9. S5.5-4. Dumas F, Bougouin W, Geri G, et al. Emergency PCI in post-cardiac arrest patients without ST-segment elevation pattern: insights from the PROCAT II registry. JACC Cardiovasc Interv. 2016;9:1011 8. S5.5-5. Ngaage DL, Cale AR, Cowen ME, et al. Early and late survival after surgical revascularization for ischemic ventricular fibrillation/tachy- cardia. Ann Thorac Surg. 2008;85:1278 81. S5.5-6. Milojevic M, Head SJ, Parasca CA, et al. Causes of death following PCI versus CABG in complex CAD: 5-year follow-up of SYNTAX. J Am Coll Cardiol. 2016;67:42 55. S5.5-7. Carson P, Wertheimer J, Miller A, et al. The STICH trial (Surgical Treatment for Ischemic Heart Failure): mode-of-death results. JACC Heart Fail. 2013;1:400 8. S5.5-8. Davis JA, Cecchin F, Jones TK, et al. Major coronary artery anomalies in a pediatric population: incidence and clinical importance. J Am Coll Cardiol. 2001;37:593 7. S5.5-9. Bagnall RD, Weintraub RG, Ingles J, et al. A prospective study of sudden cardiac death among children and young adults. N Engl J Med. 2016;374:2441 52. S5.5-10. Smallman DP, Webber BJ, Mazuchowski EL, et al. Sudden cardiac death associated with physical exertion in the US military, 2005 2010. BJ Sports Med. 2016;50:118 23. S5.5-11. Maron BJ, Doerer JJ, Haas TS, et al. Sudden deaths in young com- petitive athletes: analysis of 1866 deaths in the United States, 1980 2006. Circulation. 2009;119:1085 92. S5.5-12. Krasuski RA, Magyar D, Hart S, et al. Long-term outcome and impact of surgery on adults with coronary arteries originating from the opposite coronary cusp. Circulation. 2011;123:154 62. S5.5-13. Layser RB, Savage MP, Halpern EJ. Anomalous coronary arteries: analysis of clinical outcome based upon arterial course and surgical intervention in an adult population. Acad Radiol. 2016;23:1015 23. S5.5-14. Taylor AJ, Rogan KM, Virmani R. Sudden cardiac death associ- ated with isolated congenital coronary artery anomalies. J Am Coll Cardiol. 1992;20:640 7. 5.5.1. Surgery for Arrhythmia Management S5.5.1-1. Anter E, Hutchinson MD, Deo R, et al. Surgical ablation of refractory ventricular tachycardia in patients with nonischemic cardiomyopa- thy. Circ Arrhythm Electrophysiol. 2011;4:494 500. S5.5.1-2. Bhavani SS, Tchou P, Saliba W, et al. Surgical options for refractory ventricular tachycardia. J Card Surg. 2007;22:533 4. S5.5.1-3. Choi EK, Nagashima K, Lin KY, et al. Surgical cryoablation for ven- tricular tachyarrhythmia arising from the left ventricular outflow tract region. Heart Rhythm. 2015;12:1128 36. S5.5.1-4. Kumar S, Barbhaiya CR, Sobieszczyk P, et al. Role of alternative interventional procedures when endo- and epicardial catheter ablation attempts for ventricular arrhythmias fail. Circ Arrhythm Electrophysiol. 2015;8:606 15. S5.5.1-5. Mulloy DP, Bhamidipati CM, Stone ML, et al. Cryoablation dur- ing left ventricular assist device implantation reduces postop- erative ventricular tachyarrhythmias. J Thorac Cardiovasc Surg. 2013;145:1207 13. S5.5.1-6. Patel M, Rojas F, Shabari FR, et al. Safety and feasibility of open chest epicardial mapping and ablation of ventricular tachycardia during the period of left ventricular assist device implantation. J Cardiovasc Electrophysiol. 2016;27:95 101. S5.5.1-7. Sartipy U, Albage A, Straat E, et al. Surgery for ventricular tachycar- dia in patients undergoing left ventricular reconstruction by the Dor procedure. Ann Thorac Surg. 2006;81:65 71. CLINICAL STATEMENTS AND GUIDELINES 5.6. Autonomic Modulation S5.6-1. Krittayaphong R, Bhuripanyo K, Punlee K, et al. Effect of ateno- lol on symptomatic ventricular arrhythmia without structural heart disease: a randomized placebo-controlled study. Am Heart J. 2002;144:e10. S5.6-2. Vaseghi M, Barwad P, Malavassi Corrales FJ, et al. Cardiac sympa- thetic denervation for refractory ventricular arrhythmias. J Am Coll Cardiol. 2017;69:3070 80. S5.6-3. Vaseghi M, Gima J, Kanaan C, et al. Cardiac sympathetic denerva- tion in patients with refractory ventricular arrhythmias or electri- cal storm: intermediate and long-term follow-up. Heart Rhythm. 2014;11:360 6. S5.6-4. Schwartz PJ, Motolese M, Pollavini G. Prevention of sudden car- diac death after a first myocardial infarction by pharmacologic or surgical antiadrenergic interventions. J Cardiovasc Electrophysiol. 1992;3:2 16. S5.6-5. Shen MJ, Zipes DP. Role of the autonomic nervous system in modu- lating cardiac arrhythmias. Circ Res. 2014;114:1004 21. S5.6-6. Ajijola OA, Lellouche N, Bourke T, et al. Bilateral cardiac sympa- thetic denervation for the management of electrical storm. J Am Coll Cardiol. 2012;59:91 2. 6. ACUTE MANAGEMENT OF SPECIFIC VA S6-1. Link MS, Berkow LC, Kudenchuk PJ, et al. Part 7: adult advanced cardiovascular life support: 2015 American Heart Association guide- lines update for cardiopulmonary resuscitation and emergency car- diovascular care. Circulation. 2015;132 suppl 2:S444 64. S6-2. Stiell IG, Wells GA, Field B, et al. Advanced cardiac life support in out-of-hospital cardiac arrest. N Engl J Med. 2004;351:647 56. S6-3. Sasson C, Rogers MA, Dahl J, et al. Predictors of survival from out- of-hospital cardiac arrest: a systematic review and meta-analysis. Circ Cardiovasc Qual Outcomes. 2010;3:63 81. S6-4. Dorian P, Cass D, Schwartz B, et al. Amiodarone as compared with lidocaine for shock-resistant ventricular fibrillation. N Engl J Med. 2002;346:884 90. S6-5. Kudenchuk PJ, Brown SP, Daya M, et al. Amiodarone, lidocaine, or placebo in out-of-hospital cardiac arrest. N Engl J Med. 2016; 1711 22. S6-6. Kudenchuk PJ, Cobb LA, Copass MK, et al. Amiodarone for resusci- tation after out-of-hospital cardiac arrest due to ventricular fibrilla- tion. N Engl J Med. 1999;341:871 8. S6-7. Spaulding CM, Joly LM, Rosenberg A, et al. Immediate coronary angiography in survivors of out-of-hospital cardiac arrest. N Engl J Med. 1997;336:1629 33. S6-8. Cronier P, Vignon P, Bouferrache K, et al. Impact of routine percuta- neous coronary intervention after out-of-hospital cardiac arrest due to ventricular fibrillation. Crit Care. 2011;15:R122. S6-9. Zanuttini D, Armellini I, Nucifora G, et al. Impact of emergency coro- nary angiography on in-hospital outcome of unconscious survivors after out-of-hospital cardiac arrest. Am J Cardiol. 2012;110:1723 8. S6-10. Dumas F, Bougouin W, Geri G, et al. Emergency PCI in post-cardiac arrest patients without ST-segment elevation pattern: insights from the PROCAT II registry. JACC Cardiovasc Interv. 2016;9:1011 8. S6-11. Gorgels AP, van den Dool A, Hofs A, et al. Comparison of procain- amide and lidocaine in terminating sustained monomorphic ven- tricular tachycardia. Am J Cardiol. 1996;78:43 6. S6-12. Markel DT, Gold LS, Allen J, et al. Procainamide and survival in ven- tricular fibrillation out-of-hospital cardiac arrest. Acad Emerg Med. 2010;17:617 23. S6-13. Ortiz M, Martin A, Arribas F, et al. Randomized comparison of intra- venous procainamide vs. intravenous amiodarone for the acute treatment of tolerated wide QRS tachycardia: the PROCAMIO study. Eur Heart J. 2017;38:1329 35. S6-14. Herlitz J, Ekstrom L, Wennerblom B, et al. Lidocaine in out-of-hos- pital ventricular fibrillation. Does it improve survival? Resuscitation. 1997;33:199 205. S6-15. Kudenchuk PJ, Newell C, White L, et al. Prophylactic lidocaine for post resuscitation care of patients with out-of-hospital ventricular fibrillation cardiac arrest. Resuscitation. 2013;84:1512 8. S6-16. Teo KK, Yusuf S, Furberg CD. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. An overview of results from randomized controlled trials. JAMA. 1993;270:1589 95. S6-17. Nademanee K, Taylor R, Bailey WE, et al. Treating electrical storm: sympathetic blockade versus advanced cardiac life support-guided therapy. Circulation. 2000;102:742 7. S6-18. Piccini JP, Hranitzky PM, Kilaru R, et al. Relation of mortality to failure to prescribe beta blockers acutely in patients with sustained ventric- ular tachycardia and ventricular fibrillation following acute myocar- dial infarction (from the VALsartan In Acute myocardial iNfarcTion trial [VALIANT] Registry). Am J Cardiol. 2008;102:1427 32. S6-19. Callaham M, Madsen CD, Barton CW, et al. A randomized clinical trial of high-dose epinephrine and norepinephrine vs standard-dose epinephrine in prehospital cardiac arrest. JAMA. 1992;268:2667 72. S6-20. Donnino MW, Salciccioli JD, Howell MD, et al. Time to adminis- tration of epinephrine and outcome after in-hospital cardiac arrest with non-shockable rhythms: retrospective analysis of large in-hos- pital data registry. BMJ. 2014;348:g3028. S6-21. Gueugniaud PY, Mols P, Goldstein P, et al. A comparison of repeated high doses and repeated standard doses of epinephrine for cardiac arrest outside the hospital. European Epinephrine Study Group. N Engl J Med. 1998;339:1595 601. S6-22. Hagihara A, Hasegawa M, Abe T, et al. Prehospital epinephrine use and survival among patients with out-of-hospital cardiac arrest. JAMA. 2012;307:1161 8. S6-23. Jacobs IG, Finn JC, Jelinek GA, et al. Effect of adrenaline on sur- vival in out-of-hospital cardiac arrest: a randomised double-blind placebo-controlled trial. Resuscitation. 2011;82:1138 43. S6-24. Koscik C, Pinawin A, McGovern H, et al. Rapid epinephrine admin- istration improves early outcomes in out-of-hospital cardiac arrest. Resuscitation. 2013;84:915 20. S6-25. Ho DS, Zecchin RP, Richards DA, et al. Double-blind trial of ligno- caine versus sotalol for acute termination of spontaneous sustained ventricular tachycardia. Lancet. 1994;344:18 23. S6-26. Somberg JC, Bailin SJ, Haffajee CI, et al. Intravenous lidocaine ver- sus intravenous amiodarone (in a new aqueous formulation) for incessant ventricular tachycardia. Am J Cardiol. 2002;90:853 9. S6-27. Hassan TB, Jagger C, Barnett DB. A randomised trial to investigate the efficacy of magnesium sulphate for refractory ventricular fibril- lation. Emerg Med J. 2002;19:57 62. S6-28. Thel MC, Armstrong AL, McNulty SE, et al. Randomised trial of magnesium in in-hospital cardiac arrest. Duke Internal Medicine Housestaff. Lancet. 1997;350:1272 6. S6-29. Elizari MV, Martinez JM, Belziti C, et al. Morbidity and mortality following early administration of amiodarone in acute myocardial infarction. GEMICA study investigators, GEMA Group, Buenos Aires, Argentina. Grupo de Estudios Multicentricos en Argentina. Eur Heart J. 2000;21:198 205. S6-30. Belhassen B, Horowitz LN. Use of intravenous verapamil for ven- tricular tachycardia. Am J Cardiol. 1984;54:1131 3. S6-31. Buxton AE, Marchlinski FE, Doherty JU, et al. Hazards of intrave- nous verapamil for sustained ventricular tachycardia. Am J Cardiol. 1987;59:1107 10. S6-32. Zipes DP, Camm AJ, Borggrefe M, et al. ACC/AHA/ESC 2006 guide- lines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines. Circulation. 2006;114:e385 484. S6-33. Cobb LA, Fahrenbruch CE, Walsh TR, et al. Influence of cardiopul- monary resuscitation prior to defibrillation in patients with out-of- hospital ventricular fibrillation. JAMA. 1999;281:1182 8. S6-34. Cobb LA, Weaver WD, Fahrenbruch CE, et al. Community-based interventions for sudden cardiac death. Impact, limitations, and changes. Circulation. 1992;85 suppl:I98 I102. S6-35. Weisfeldt ML, Becker LB, Resuscitation after cardiac arrest: a 3-phase time-sensitive model. JAMA. 2002;288:3035 8. S6-36. Wik L, Hansen TB, Fylling F, et al. Delaying defibrillation to give basic cardiopulmonary resuscitation to patients with out-of-hospital ven- tricular fibrillation: a randomized trial. JAMA. 2003;289:1389 95. S6-37. Neumar RW, Otto CW, Link MS, et al. Part 8: adult advanced cardio- vascular life support: 2010 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation. 2010;122 suppl 2:S729 67. CLINICAL STATEMENTS AND GUIDELINES S6-38. Connolly SJ, Hallstrom AP, Cappato R, et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention tri- als. AVID, CASH and CIDS studies. Antiarrhythmics vs implant- able defibrillator study. Cardiac Arrest Study Hamburg. Canadian Implantable Defibrillator Study. Eur Heart J. 2000;21:2071 8. S6-39. Kern KB. Optimal treatment of patients surviving out-of-hospital cardiac arrest. JACC Cardiovasc Intervent. 2012;5:597 605. S6-40. Perkins GD, Jacobs IG, Nadkarni VM, et al. Cardiac arrest and car- diopulmonary resuscitation outcome reports: update of the Utstein Resuscitation Registry Templates for out-of-hospital cardiac arrest: a statement for healthcare professionals from a task force of the International Liaison Committee on Resuscitation (American Heart Association, European Resuscitation Council, Australian and New Zealand Council on Resuscitation, Heart and Stroke Foundation of Canada, InterAmerican Heart Foundation, Resuscitation Council of Southern Africa, Resuscitation Council of Asia); and the American Heart Association Emergency Cardiovascular Care Committee and the Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation. Circulation. 2015;132:1286 300. S6-41. Link MS, Myerburg RJ, Estes NA 3rd. Eligibility and disqualifica- tion recommendations for competitive athletes with cardiovascular abnormalities: Task Force 12: emergency action plans, resuscitation, cardiopulmonary resuscitation, and automated external defibrilla- tors: a scientific statement from the American Heart Association and American College of Cardiology. Circulation. 2015;132:e334 8. S6-42. Joglar JA, Page RL. Out-of-hospital cardiac arrest are drugs ever the answer? N Engl J Med. 2016;374:1781 2. 7. ONGOING MANAGEMENT OF VA AND SCD RISK RELATED TO SPECIFIC DISEASE STATES 7.1. Ischemic Heart Disease 7.1.1. Secondary Prevention of SCD in Patients With Ischemic Heart Disease S7.1.1-1. The AVID Investigators. A comparison of antiarrhythmic-drug ther- apy with implantable defibrillators in patients resuscitated from near- fatal ventricular arrhythmias. N Engl J Med. 1997;337:1576 83. S7.1.1-2. Connolly SJ, Gent M, Roberts RS, et al. Canadian implantable defibrillator study (CIDS): a randomized trial of the implant- able cardioverter defibrillator against amiodarone. Circulation. 2000;101:1297 302. S7.1.1-3. Connolly SJ, Hallstrom AP, Cappato R, et al. Meta-analysis of the implantable cardioverter defibrillator secondary preven- tion trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg. Canadian Implantable Defibrillator Study. Eur Heart J. 2000;21: 2071 8. S7.1.1-4. Kuck KH, Cappato R, Siebels J, et al. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg (CASH). Circulation. 2000;102:748 54. S7.1.1-5. Raitt MH, Renfroe EG, Epstein AE, et al. 